Stories

Denali Therapeutics

Neurodegenerative disease has remained an undefeated adversary for too long.

That needed to change. Through our affiliate FBRI, F-Prime has had a long-standing commitment to cure neurodegenerative diseases. But all previous disease-modifying trials in this arena had failed. In the past decade, though, major scientific insights into the underlying genetic causes and biological processes—along with new translational medicine tools—gave us hope for a different future.

Flywire

While preparing to attend MIT in 2008, an international student was tasked with sending his international tuition payment to the university- but the entire process lacked transparency.

Orchard Therapeutics

Prof. Bobby Gaspar wanted to solve a big puzzle.

But he only had a few pieces in hand. He and his co-founders had some of the most exciting-edge gene therapy medicines-and clinical data showing they worked-but that wasn't enough.

PatientPing

Patients get care from many providers. When these caregivers don’t coordinate, it’s dangerous and expensive.

Could this be improved by solving a communication problem?

Toast

From the willingness to listen and the ability innovate in the face of failure, a Boston unicorn is born.

Steve, Aman and Jon were at dinner when they realized the restaurant industry needed a serious tech upgrade. The three MIT grads had met at enterprise software company Endeca, and had been thinking of starting their own company in the mobile commerce space.

Ultragenyx

Emil Kakkis has always been driven to solve difficult problems.

When he approached us, he was looking for an investor who would understand rare diseases the way he did. His vision was to build a mission-driven company to treat rare and ultra-rare genetic diseases—all the way from concept to globally-approved drugs.